MedTrace Logo

Fox BioNet Project: LRRK2-002

NCT03545425 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 114

Last updated 2021-09-08

No results posted yet for this study

Summary

The overall objective of this study is to determine whether LRRK2 kinase activity and/or mitochondrial DNA (mtDNA) damage could serve as potential biomarkers in PD.

Conditions

  • Parkinson Disease

Interventions

PROCEDURE

Biofluid samplings

Blood and Urine

Sponsors & Collaborators

  • University Health Network, Toronto

    collaborator OTHER

  • Indiana University

    collaborator OTHER

  • University of Rochester

    collaborator OTHER

  • Michael J. Fox Foundation for Parkinson's Research

    lead OTHER

Principal Investigators

  • Connie Marras, MD · University Health Network, Toronto

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-16
Primary Completion
2020-04-30
Completion
2020-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03545425 on ClinicalTrials.gov